QHSLab Publishes Studies on Digital Assessment Tools

QHSLab ( (USAQ) ) has shared an update.

On June 3, 2025, QHSLab, Inc. announced the publication of two peer-reviewed studies validating the effectiveness of their digital assessment tools in primary care. These studies, released in the last week of May 2025, demonstrate the clinical and economic benefits of QHSLab’s tools, including improved mental health outcomes for patients with allergic rhinitis and the development of the Q-Scale for predicting healthcare overutilization. These findings support QHSLab’s strategy of integrating reimbursable digital medicine tools into primary care, enhancing patient care, and optimizing resource utilization, which could lead to increased provider adoption and revenue growth.

Spark’s Take on USAQ Stock

According to Spark, TipRanks’ AI Analyst, USAQ is a Neutral.

USA Equities receives a modest score due to significant financial challenges, including negative equity and profitability issues, despite robust revenue growth and cash flow improvements. The mixed technical indicators and negative valuation metrics further weigh down the score. However, the score is bolstered by positive corporate events, including strategic partnerships and record revenue growth, highlighting potential for future success.

To see Spark’s full report on USAQ stock, click here.

More about QHSLab

QHSLab, Inc. is a medical device company that provides digital healthcare solutions and point-of-care diagnostic tests to primary care physicians. Their products and services leverage advanced artificial intelligence algorithms to enhance patient monitoring and medical care, while also offering rapid-response diagnostic tests to improve healthcare efficiency and physician revenues.

Average Trading Volume: 19,176

Technical Sentiment Signal: Buy

Current Market Cap: $2.2M

For an in-depth examination of USAQ stock, go to TipRanks’ Stock Analysis page.